ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT03964727

Public ClinicalTrials.gov record NCT03964727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Study identification

NCT ID
NCT03964727
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
227 participants

Conditions and interventions

Interventions

  • Sacituzumab Govitecan-hziy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 14, 2019
Primary completion
Jan 14, 2025
Completion
Nov 30, 2026
Last update posted
Apr 27, 2026

2019 – 2026

United States locations

U.S. sites
31
U.S. states
21
U.S. cities
28
Facility City State ZIP Site status
Alaska Oncology & Hematology, LLC Anchorage Alaska 99508
USOR - Arizona Oncology - Glendale - Saguaro Cancer Center Glendale Arizona 85308
Arizona Oncology Associates PC-HAL Goodyear Arizona 85395
Highlands Oncology Group Springdale Arkansas 72762
UCLA Hematology/Oncology Los Angeles California 90095
TRIO-US Central Administration Whittier California 90602
University of Colorado Hospital - Anschutz Cancer Pavilion Aurora Colorado 80045
Smilow Cancer Hospital at Yale New Haven Connecticut 06520
SIU School of Medicine, Simmons Cancer Institute at SIU Springfield Illinois 62702
PathGroup Labs, LLC Fort Wayne Indiana 46804
Parkview Research Center Fort Wayne Indiana 46845
University of Kentucky Medical Center Lexington Kentucky 40536
Christus Highland Cancer Treatment Center Shreveport Louisiana 71105
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
North Mississippi Medical Center - Hematology and Oncology - Tupelo Tupelo Mississippi 38801
Washington University School of Medicine - Siteman Cancer Center St Louis Missouri 63110
David C. Pratt Center St Louis Missouri 63141
Comprehensive Cancer of Nevada Las Vegas Nevada 89052
New York Oncology Hematology - Albany Medical Center Albany New York 12208
Memorial Sloan Kettering Cancer Center New York New York 10065
Weill Cornell Medicine - Upper East Side New York New York 10065
Montefiore Medical Center The Bronx New York 10467
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Willamette Valley Cancer Institute and Research Center - Eugene Eugene Oregon 97401
Tennessee Oncology, PLLC Nashville Tennessee 37203
The University of Texas MD Anderson Cancer Center Houston Texas 77030
Texas Oncology - Tyler Tyler Texas 75702
Blue Ridge Cancer Care - Wytheville Blacksburg Virginia 24060
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Providence Regional Cancer Partnership Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03964727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03964727 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →